Your browser doesn't support javascript.
loading
Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4.
Londregan, Allyn T; Aitmakhanova, Karlygash; Bennett, James; Byrnes, Laura J; Canterbury, Daniel P; Cheng, Xiayun; Christott, Thomas; Clemens, Jennifer; Coffey, Steven B; Dias, João M; Dowling, Matthew S; Farnie, Gillian; Fedorov, Oleg; Fennell, Kimberly F; Gamble, Vicki; Gileadi, Carina; Giroud, Charline; Harris, Michael R; Hollingshead, Brett D; Huber, Kilian; Korczynska, Magdalena; Lapham, Kimberly; Loria, Paula M; Narayanan, Arjun; Owen, Dafydd R; Raux, Brigitt; Sahasrabudhe, Parag V; Ruggeri, Roger B; Sáez, Laura Díaz; Stock, Ingrid A; Thuma, Benjamin A; Tsai, Andy; Varghese, Alison E.
Afiliação
  • Londregan AT; Pfizer Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.
  • Aitmakhanova K; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Bennett J; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Byrnes LJ; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Canterbury DP; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Cheng X; Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.
  • Christott T; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Clemens J; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Coffey SB; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Dias JM; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Dowling MS; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Farnie G; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Fedorov O; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Fennell KF; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Gamble V; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Gileadi C; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Giroud C; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Harris MR; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Hollingshead BD; Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.
  • Huber K; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Korczynska M; Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.
  • Lapham K; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Loria PM; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Narayanan A; Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.
  • Owen DR; Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.
  • Raux B; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Sahasrabudhe PV; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Ruggeri RB; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Sáez LD; Centre for Medicines Discovery, NDM, University of Oxford, Oxford OX3 7DQ, U.K.
  • Stock IA; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Thuma BA; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Tsai A; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
  • Varghese AE; Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
J Med Chem ; 66(1): 460-472, 2023 01 12.
Article em En | MEDLINE | ID: mdl-36562986
ABSTRACT
A series of small-molecule YEATS4 binders have been discovered as part of an ongoing research effort to generate high-quality probe molecules for emerging and/or challenging epigenetic targets. Analogues such as 4d and 4e demonstrate excellent potency and selectivity for YEATS4 binding versus YEATS1,2,3 and exhibit good physical properties and in vitro safety profiles. A new X-ray crystal structure confirms direct binding of this chemical series to YEATS4 at the lysine acetylation recognition site of the YEATS domain. Multiple analogues engage YEATS4 with nanomolar potency in a whole-cell nanoluciferase bioluminescent resonance energy transfer assay. Rodent pharmacokinetic studies demonstrate the competency of several analogues as in vivo-capable binders.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Processamento de Proteína Pós-Traducional / Regulação da Expressão Gênica Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Processamento de Proteína Pós-Traducional / Regulação da Expressão Gênica Idioma: En Ano de publicação: 2023 Tipo de documento: Article